Research

Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial)


 

Table 3. AEs Occurring in ≥10% of Patients Overalla
NUMBER OF PATIENTS (%)
TYPE OF AEZOLEDRONIC ACID 4 MG IV FOR 15 MINUTES (N = 85)ZOLEDRONIC ACID 4 MG IV FOR 30 MINUTES (N = 84)TOTAL (N = 169)
Blood and lymphatic system disorders
Anemia19 (22)27 (32)46 (27)
Neutropenia6 (7)12 (14)18 (11)
Gastrointestinal disorders
Constipation20 (24)21 (25)41 (24)
Diarrhea14 (17)20 (24)34 (20)
Nausea18 (21)27 (32)45 (27)
Vomiting10 (12)14 (17)24 (14)
General disorders
Fatigue30 (35)41 (49)71 (42)
Pain7 (8)10 (12)17 (10)
Pain in extremity14 (17)16 (19)30 (18)
Peripheral edema13 (15)20 (24)33 (20)
Pyrexia15 (18)19 (23)34 (20)
Infections and infestations
Pneumonia11 (13)7 (8)18 (11)
Upper respiratory tract infection13 (15)13 (16)26 (15)
Metabolism and nutrition disorders
Anorexia8 (9)9 (11)17 (10)
Hypokalemia12 (14)13 (15)25 (14)
Musculoskeletal and connective tissue disorders
Arthralgia10 (11)16 (19)26 (15)
Asthenia9 (10)13 (16)22 (13)
Back pain19 (22)20 (24)39 (23)
Bone pain10 (12)11 (13)21 (12)
Nervous system disorders
Dizziness11 (13)10 (12)21 (12)
Peripheral neuropathy7 (8)15 (18)22 (13)
Psychiatric disorders
Insomnia10 (12)14 (17)24 (14)
Respiratory, thoracic, and mediastinal disorders
Cough13 (15)15 (18)28 (17)
Dyspnea15 (18)17 (20)32 (19)
Skin and subcutaneous tissue disorders
Rash9 (11)12 (14)21 (12)

AE = adverse event; IV = intravenous

a Safety population excluding patients with protocol violations

The numbers of deaths, trial discontinuations, and treatment interruptions due to AEs were similar between the two groups as well. Deaths (9 [10.6%] 15-minute group vs 6 [7.1%] 30-minute group) were not suspected to be related to zoledronic acid. Eight patients in each treatment group discontinued therapy because of an AE; events leading to treatment discontinuation that were suspected to be related to zoledronic acid occurred in two patients in the 15-minute group (skeletal pain and ONJ) and one patient in the 30-minute group (jaw pain). AEs that required treatment interruption occurred in eight and nine patients in the 15-minute and 30-minute groups, respectively.

AEs of special interest included those related to kidney dysfunction, cardiac arrhythmias, SREs, and ONJ. The number of patients reporting overall kidney and urinary disorders was the same in the two treatment groups (14 patients in each group); however, acute renal failure was reported more frequently in patients receiving the 15-minute infusion compared with the 30-minute infusion (four patients [5%] vs one patient [1%] in 30-minute group). Details of these five patients are presented in Table 4. AEs related to cardiac rhythm occurred in 20 patients while on study; however, only one case of bradycardia was suspected to be related to zoledronic acid therapy (in the 30-minute group). The incidence of SREs at 2 years was comparable in the two groups (19% in 15-minute group vs 21% in 30-minute group). The time to onset of SREs was longer in the 15-minute group (222 vs 158 days), but this was not statistically significant. A total of 10 patients with suspected ONJ were identified, with three patients in the 15-minute group (all moderate) and seven patients in the 30-minute group (mild [n = 5], moderate [n = 1], severe [n = 1]). Six of these patients received bisphosphonates before entering the study (four patients received no prior bisphosphonates), but the length of previous bisphosphonate therapy varied (0–30 months). Patients with suspected ONJ were assessed by clinicians and referred to dental professionals for further evaluation.

Table 4. Patients Experiencing Acute Renal Failure
PATIENT DEMOGRAPHICSTYPE OF MMMEDICAL HISTORYCONCURRENT MEDICATIONSaACUTE RENAL FAILURE DETAILSOUTCOME
Zoledronic acid 4 mg IV for 15 minutes
73-year-old female CaucasianIgGAnemia, cardiomyopathy, CHF, cholecystectomy, benign breast lump removal, CAD, DM, dyslipidemia, central venous catheterization, chronic renal failure, GERD, hypercholesterolemia, HTN, hysterectomy, mycobacterial infection, hemorrhoids, B-cell lymphoma, seborrheic keratosis, tonsillectomyAt start of study: aspirin, losartan, digoxin, hydrochlorothiazide/lorsartan, fluconazole, folic acid, atorvastatin, vitamins, warfarinDuring study: ethambutol dihydrochloride, moxifloxacin, rifabutin, fenofibrate, omeprazole, diuretics, nitroglycerin patch, angiotensin-converting enzyme inhibitors, hydroxyzine, loratadine, furosemide, vancomycin, pantoprozole, piperacillin/tazobactam, clarithromycinMyeloma kidney mass consistent with myeloma kidney found during study; approximately 2 weeks later the patient developed severe infection that culminated in septic shock, with acute renal failureNephrologist considered renal insufficiency to be partly related to past history of large-cell lymphoma and chemotherapy; patient was discharged to hospice and died of acute renal failure secondary to myeloma
71-year-old female CaucasianIgABack pain, cholecystectomy, constipation, CAD, NIDDM, hypercholesterolemia, HTN, insomnia, left knee operation, neuralgia, obesity, osteoarthritis, hysterectomy, hypoacusis, seasonal allergies, urinary incontinenceAt start of study: zolpidem, amitriptyline, loratidine, tolterodine l-tartrate, valsartan, metrotoprolol, furosemide, ibuprofen, clonazepam, gabapentin, liodcaine, hydrocodone/acetaminophen, quinine sulfate, simvastatin During study: calcium, multivitamins, lactulose, trazodone, hydromorphone, cyclobenzaprine, glipizide, macrogol, lorazepam, methadone, potassium, lisinopril, furosemide, meperidine, promethazineDeveloped moderate acute renal failure on the day of her first dose; considered not associated with zoledronic acidRenal ultrasound showed arterial stenosis; resolved approximately 1 month after diagnosis
65-year-old male CaucasianIgGOxycodone hypersensitivity, anemia, back pain, spine metastases, spinal compression fracture, depression, fatigue, inguinal hernia repair, spinal fusion (L1–L3) surgery, bilateral hip arthroplasty, pain, pneumonia, staphylococcal infectionAt start of study: fluconazole, morphine sulfate, oxycodone/acetaminophen During study: naproxen, darbepoietin alfa, sodium ferrifluconate, calcium with vitamin D, cephalexin, dexamethasone, alginic acid, docusate, heparin, sodium polystyrene, levofloxacin, filgrastim, lansoprazoleAfter 5 doses of zoledronic acid, patient developed severe acute renal failure with elevated SCr; not suspected to be related to zoledronic acidResolved 9 days later following treatment with cephalexin and dexamethasone
56-year-old female CaucasianIgAOsteolysis, cataract surgery, constipation, bone lesions, hypercholesterolemia, HTN, musculoskeletal pain, anorexiaAt start of study: ibuprofen, oxycodone, propoxyphene/acetaminophen, hydrocodone/acetaminophen, valsartan, calcium/vitamin D, potassium chloride, docusate sodiumDuring study: vancomycin, acyclovirApproximately 1 week after 9th zoledronic acid dose, patient developed acute renal failure with an increased SCr (12.5 mg/dL); not suspected to be related to zoledronic acidResulted from myeloma progression to plasma cell leukemia; emergency dialysis performed; catheter-related sepsis occurred approximately 1 month later, and patient died of sepsis and disease progression
Zoledronic acid 4 mg IV for 30 minutes
80-year-old male African AmericanIgGAnemia, arteriosclerotic heart disease, bilateral ankle swelling/pain, degenerative joint disease, dyspnea on exertion, fatigue, GERD, HTN, neutropenia, shoulder pain, vasovagal syncopeAt start of study: aspirin, atenolol, multivitamin, doxazosin, fosinopril, hydrochlorothiazide, amlodipine besylate, simvastatinDuring study: darbepoietin alfa, warfarin sodium, furosemide, omeprazole, calcium carbonateApproximately 1 month after 2nd dose, patient experienced increased SCr (2.9 mg/dL, 53% increase from baseline); relationship to zoledronic acid unknownDiscontinued from study after 2nd dose, and SCr remained elevated for 2 months following discontinuation

CAD = coronary artery disease; CHF = congestive heart failure; DM = diabetes mellitus; GERD = gastroesophageal reflux disease; HTN = hypertension; MM = multiple myeloma; NIDDM = non-insulin-dependent diabetes mellitus; SCr = serum creatinine

a Reported at the study start and during the study

Pages

Recommended Reading

Rituximab Maintenance Approved in Follicular Lymphoma
MDedge Hematology and Oncology
Rituximab Maintenance Approved in Follicular Lymphoma
MDedge Hematology and Oncology
Brentuximab and Refractory Hodgkin's Lymphoma
MDedge Hematology and Oncology
First-Line Lymphoma Treatments
MDedge Hematology and Oncology
Multiple Myeloma in the Elderly
MDedge Hematology and Oncology
Rituximab Maintenance Approved in Follicular Lymphoma
MDedge Hematology and Oncology
FDA warns of possible link between breast implants and ALCL
MDedge Hematology and Oncology
Phase 3 trial of pixantrone leaves FDA uneasy
MDedge Hematology and Oncology
ODAC votes against one leukemia, one NHL drug
MDedge Hematology and Oncology
Denileukin diftitox has significant, durable responses in CTCL
MDedge Hematology and Oncology